JP Morgan Downgrades Global Blood Therapeutics to Neutral, Announces $36 Price Target
JP Morgan analyst Tessa Romero downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and announces $36 price target.
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.